About Fortrea Holdings Inc
- Industry: Life Sciences Tools & Services
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.fortrea.com/
Frequently Asked Questions
What is the 52-week range for FTRE?
The 52-week high is $21.39 and the 52-week low is $8.39.
What is the P/E ratio for FTRE?
The P/E ratio data is currently unavailable.
What is the dividend yield for FTRE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -15.53%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3.18%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.83.
Analyst Recommendation Trends
Wall Street analyst consensus for FTRE over the last few months:
Latest FTRE News
1 Momentum Stock to Research Further and 2 We Turn Down
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
'HHS launches project to speed up clinical trials' - Axios
https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign
3 Healthcare Stocks That Concern Us
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.7% gain over the past six months, beating the S&P 500 by 25.6 percentage points.
UBS Initiates Coverage On Fortrea Holdings with Neutral Rating, Announces Price Target of $22
UBS analyst Kevin Caliendo initiates coverage on Fortrea Holdings (NASDAQ:FTRE) with a Neutral rating and announces Price Target of $22.
Fortrea (FTRE) Stock Could Be 46% Undervalued As Deal Questions Build
Fortrea Holdings has delivered a sharp share price move over the past year, which puts the focus squarely on whether that jump lines up with the cash the business can generate. With the stock now reflecting both recent momentum and fresh deal activity, investors are asking if today’s valuation is grounded in the company’s underlying cash flows or leaning more on optimism. Fortrea Holdings has returned about 129.1% over the past year, which puts meaningful pressure on the cash flow outlook to...
2 Small-Cap Stocks to Research Further and 1 Facing Challenges
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
CRO consolidation keeps rolling. What does that mean for pharma?
While M&A expands one-stop shop capabilities at large CROs, pharma companies could face tradeoffs around niche expertise and service continuity.
2 of Wall Street’s Favorite Stocks to Target This Week and 1 Facing Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees. Included in these awards were grants of employment inducement awards to Jason Knoblauch, the Company’s recently appointed Chief Financial Officer, as an inducement material to
Fortrea to Participate in September Investor Conferences
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September: Baird 2026 Global Healthcare Conference (NYC) Date: Tuesday, September 15, 2026Format: Fireside Chat & 1x1 and Group MeetingsTime: 2:00 -2:30 PM EDTWebcast: FTRE Baird Webcast Deutsche Bank 2026 Healthcar
Fortrea Reinstates Jason Knoblauch As CFO
David Smith, a current director on the Board, had acted as Interim Chief Financial Officer and principal financial officer during Mr. Knoblauch’s leave of absence. In connection with Mr. Knoblauch’s reinstatement, Mr.
Stocks making big moves this week: SAIC, Reddit, Fortrea, GitLab, and G-III
Check out the companies making headlines this week:
Fortrea: A Surprising M&A Move During The Recovery
Fortrea's stock surged from $4 to $18 on backlog growth and margin gains. Click to read this analysis and for more details about investing in FTRE.
Stocks making big moves yesterday: Limbach, FuelCell Energy, Ollie's, Fortrea, and G-III
Check out the companies making headlines yesterday:
Fortrea (FTRE) Stock Is Up, What You Need To Know
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 3% in the afternoon session after the company agreed to acquire the Early Phase Services division of Worldwide Clinical Trials.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-10 | Knoblauch Jason Fredrick | +144,434 | - | - |
| 2026-09-09 | Russell Carrie Elizabeth | -246 | $16.85 | $4,145 |
| 2026-09-09 | Morais Mark A. | -3,149 | $16.85 | $53,061 |
| 2026-09-08 | Russell Carrie Elizabeth | -850 | - | - |
| 2026-09-08 | Russell Carrie Elizabeth | +850 | - | - |
| 2026-09-08 | Morais Mark A. | -7,157 | - | - |
| 2026-09-08 | Morais Mark A. | +7,157 | - | - |
| 2026-08-19 | Morais Mark A. | -4,892 | $18.19 | $88,985 |
| 2026-08-18 | Morais Mark A. | -11,313 | - | - |
| 2026-08-18 | Morais Mark A. | +11,313 | - | - |
| 2026-08-06 | Thakral Anshul | -55,975 | $18.06 | $1,010,908 |
| 2026-08-06 | Thakral Anshul | -55,882 | $18.17 | $1,015,376 |
| 2026-08-05 | Thakral Anshul | -50,417 | $19.28 | $972,040 |
| 2026-08-05 | Thakral Anshul | -49,452 | $19.03 | $941,072 |
| 2026-08-04 | Thakral Anshul | -416,666 | - | - |
| 2026-08-04 | Thakral Anshul | +416,666 | - | - |
| 2026-08-03 | SANDERS MACHELLE | -9,700 | $18.01 | $174,697 |
| 2026-08-03 | Smith David Ross | +15,840 | - | - |
| 2026-07-20 | Smith David Ross | +6,598 | - | - |
| 2026-06-10 | Morais Mark A. | -4,674 | $16.82 | $78,617 |
| 2026-06-10 | Ray Amrit | +12,852 | - | - |
| 2026-06-10 | Ray Amrit | -38,817 | - | - |
| 2026-06-10 | Ray Amrit | +38,817 | - | - |
| 2026-06-10 | SANDERS MACHELLE | +12,852 | - | - |
| 2026-06-10 | SANDERS MACHELLE | -38,817 | - | - |
| 2026-06-10 | SANDERS MACHELLE | +38,817 | - | - |
| 2026-06-10 | Smith David Ross | +12,852 | - | - |
| 2026-06-10 | Smith David Ross | -38,817 | - | - |
| 2026-06-10 | Smith David Ross | -18,244 | $16.34 | $298,107 |
| 2026-06-10 | Smith David Ross | +38,817 | - | - |
| 2026-06-10 | Russell Erin L | +12,852 | - | - |
| 2026-06-10 | Russell Erin L | -38,817 | - | - |
| 2026-06-10 | Russell Erin L | +38,817 | - | - |
| 2026-06-10 | Pesicka Edward A | +12,852 | - | - |
| 2026-06-10 | Pesicka Edward A | -38,817 | - | - |
| 2026-06-10 | Pesicka Edward A | +38,817 | - | - |
| 2026-06-10 | Sharbaugh William J | +12,852 | - | - |
| 2026-06-10 | NEUPERT PETER M | +12,852 | - | - |
| 2026-06-02 | Morais Mark A. | -4,866 | $15.49 | $75,374 |
| 2026-06-02 | Mcconnell Jill G. | -4,866 | $15.49 | $75,374 |
| 2026-06-01 | Morais Mark A. | -11,006 | - | - |
| 2026-06-01 | Morais Mark A. | +11,006 | - | - |
| 2026-06-01 | Mcconnell Jill G. | -11,006 | - | - |
| 2026-06-01 | Mcconnell Jill G. | +11,006 | - | - |
| 2026-05-18 | Parks Robert | -2,000 | $13.44 | $26,880 |
| 2026-05-14 | NEUPERT PETER M | -148,536 | - | - |
| 2026-05-14 | NEUPERT PETER M | +148,536 | - | - |
| 2026-03-20 | Russell Erin L | -23,946 | - | - |
| 2026-03-20 | Russell Erin L | +23,946 | - | - |
| 2026-03-16 | Morais Mark A. | -1,804 | $9.22 | $16,633 |
| 2026-03-16 | Mcconnell Jill G. | -1,804 | $9.22 | $16,633 |
| 2026-03-13 | Morais Mark A. | -4,284 | - | - |
| 2026-03-13 | Morais Mark A. | +4,284 | - | - |
| 2026-03-13 | Mcconnell Jill G. | -4,284 | - | - |
| 2026-03-13 | Mcconnell Jill G. | +4,284 | - | - |
| 2026-03-10 | Morais Mark A. | -2,300 | $9.21 | $21,183 |
| 2026-03-10 | Morais Mark A. | -2,299 | $8.93 | $20,530 |
| 2026-03-10 | Mcconnell Jill G. | -2,531 | $9.21 | $23,311 |
| 2026-03-10 | Mcconnell Jill G. | -2,530 | $8.93 | $22,593 |
| 2026-03-10 | Parks Robert | -964 | $9.21 | $8,878 |
| 2026-03-10 | Parks Robert | -963 | $8.93 | $8,600 |
| 2026-03-09 | Morais Mark A. | -13,966 | - | - |
| 2026-03-09 | Morais Mark A. | +13,966 | - | - |
| 2026-03-09 | Mcconnell Jill G. | -15,283 | - | - |
| 2026-03-09 | Mcconnell Jill G. | +15,283 | - | - |
| 2026-03-09 | Parks Robert | -5,270 | - | - |
| 2026-03-09 | Parks Robert | +5,270 | - | - |
| 2026-03-06 | Morais Mark A. | +66,667 | - | - |
| 2026-03-06 | Morais Mark A. | +52,030 | - | - |
| 2026-03-06 | Mcconnell Jill G. | +66,667 | - | - |
| 2026-03-06 | Mcconnell Jill G. | +88,450 | - | - |
| 2026-03-06 | Parks Robert | +22,893 | - | - |
| 2026-02-10 | Morais Mark A. | -590 | $14.11 | $8,325 |
| 2026-02-10 | Morais Mark A. | -589 | $13.65 | $8,040 |
| 2026-02-10 | Mcconnell Jill G. | -441 | $14.11 | $6,223 |
| 2026-02-10 | Mcconnell Jill G. | -440 | $13.65 | $6,006 |
| 2026-02-09 | Morais Mark A. | -2,255 | - | - |
| 2026-02-09 | Morais Mark A. | +2,255 | - | - |
| 2026-02-09 | Mcconnell Jill G. | -1,685 | - | - |
| 2026-02-09 | Mcconnell Jill G. | +1,685 | - | - |
| 2025-11-20 | Sharbaugh William J | +20,916 | - | - |